Komori
Ono Pharmaceutical (4528) · RiskMaterialised

Bribery Case Involving Scholarship Donations and Measures to Prevent Recurrence and Restore Trust

First written in FY2022. 1 of 1 entries say "Materialised", first in FY2022. Latest entry: FY2022.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies

Ono Pharmaceutical moved to the "Worse" side of this theme in 2022.

The whole theme swung hardest in 2022: 1 of 10 companies on the "Worse" side.

0 other companies' latest entry also says "Materialised".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 42 companies compared. The sentences above are computed from all 42.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Ono Pharmaceutical's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Bribery Case Involving Scholarship Donations and Measures to Prevent Recurrence and Restore Trust | ONO PHARMACEUTICAL CO.,LTD. (4528) | Komori